{"gene":"PPT1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1996,"finding":"PPT1 (palmitoyl-protein thioesterase) encodes a 306-amino acid glycoprotein with a 25-amino-acid signal peptide, three N-linked glycosylation sites, and consensus motifs characteristic of thioesterases; it removes palmitate groups from cysteine residues in lipid-modified proteins. Northern analysis revealed ubiquitous expression of a single 2.5-kb mRNA.","method":"cDNA and genomic cloning, sequence analysis, Northern blot","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct biochemical characterization of the gene and protein structure, foundational cloning paper replicated by multiple subsequent studies","pmids":["8786130"],"is_preprint":false},{"year":2001,"finding":"PPT1 disruption in knockout mice causes infantile neuronal ceroid lipofuscinosis (INCL)-like neurodegeneration with autofluorescent storage material, neuronal apoptosis, spasticity, seizures, and death by 10 months, demonstrating that PPT1 is the enzyme deficient in INCL. PPT1 hydrolyzes fatty acids from modified cysteine residues in proteins undergoing lysosomal degradation, in addition to hydrolyzing long-chain fatty acyl CoAs.","method":"Gene knockout mouse model, histopathology, enzymatic assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined neurological phenotype, enzymatic assays, replicated by multiple independent labs","pmids":["11717424"],"is_preprint":false},{"year":2001,"finding":"In mouse primary neurons and brain tissue, PPT1 localizes to synaptosomes and synaptic vesicles but not to lysosomes, contrasting with its classical lysosomal routing in non-neuronal cells. PPT1 is recognized by the mannose-6-phosphate receptor (M6PR) and routed to lysosomes in COS-1 cells, with a substantial fraction secreted. In polarized epithelial cells, PPT1 localizes exclusively to the basolateral site.","method":"Confocal microscopy, cryoimmunoelectron microscopy, cell fractionation, mannose-6-phosphate receptor binding assay","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal localization methods (confocal, cryo-IEM, fractionation), distinct findings in neuronal vs. non-neuronal cells","pmids":["11136716"],"is_preprint":false},{"year":2003,"finding":"Structural comparison of PPT1 and PPT2 crystal structures revealed that conformational differences in helix α4 create a solvent-exposed lipid-binding groove in PPT1 that is absent in PPT2, explaining why PPT1 can hydrolyze palmitoylcysteine and palmitoylated proteins while PPT2 preferentially hydrolyzes unbranched substrates like palmitoyl-CoA. Differences in the space between two parallel loops (β3-αA and β8-αF) above the lipid-binding groove account for the divergent substrate specificities.","method":"X-ray crystallography (PPT2 at 2.7 Å resolution), structural comparison with PPT1, in vitro substrate specificity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional validation of substrate specificity differences, mechanistic explanation at atomic level","pmids":["12855696"],"is_preprint":false},{"year":2005,"finding":"PPT1 deficiency (Ppt1Δex4 knockout mice) causes endoplasmic reticulum stress, activation of the unfolded protein response (UPR) marked by elevated phospho-eIF2α and GRP78, and activation of caspase-12 followed by caspase-3, leading to neuronal apoptosis. The palmitoylated neuronal protein GAP-43 accumulates abnormally in the ER of PPT1-deficient cells.","method":"PPT1 knockout mouse brain analysis, forced expression of GFP-GAP-43 in PPT1-deficient cells, Western blot for UPR markers (eIF2α phosphorylation, GRP78, caspase-12 cleavage)","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple biochemical assays in both mouse model and cultured cells, replicated in related studies (PMID 16644870)","pmids":["16368712"],"is_preprint":false},{"year":2006,"finding":"In human INCL brain (PPT1-deficient), ER stress-induced UPR activates caspase-4 (the human counterpart of murine caspase-12) and caspase-3, leading to apoptosis. GAP-43, a palmitoylated protein, accumulates abnormally in the ER of INCL cells. Inhibition of caspase-4 activity protects INCL cells from apoptosis.","method":"Western blot, immunofluorescence in cultured INCL cells, GFP-GAP-43 transfection and localization, caspase-4 inhibitor treatment","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Western, IF, functional rescue by inhibitor), replicated findings from murine model studies","pmids":["16644870"],"is_preprint":false},{"year":2006,"finding":"PPT1 deficiency elevates reactive oxygen species (ROS) and superoxide dismutase-2 (SOD-2) levels in INCL brain and neurospheres, leading to calcium homeostasis disruption and caspase-9 activation via mitochondrial membrane destabilization, which then activates caspase-3 and PARP cleavage (apoptosis).","method":"Analysis of PPT1-KO mouse brain tissues and cultured neurospheres from PPT1-KO fetuses; measurement of ROS, SOD-2, cleaved caspase-9, caspase-3, PARP","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO model with defined biochemical readouts, single lab, pathway placement via correlation rather than direct rescue","pmids":["16571600"],"is_preprint":false},{"year":2007,"finding":"PPT1's N-glycosylation at N197 and N232 (but not N212) is essential for its enzymatic activity and intracellular transport. PPT1 forms oligomeric complexes as demonstrated by size-exclusion chromatography and co-immunoprecipitation. PPT1 processing and trafficking differs between neuronal and non-neuronal cells. Disease-causing mutations increase both the degree of glycosylation of PPT1 and its ability to form complexes.","method":"Site-directed mutagenesis of glycosylation sites, size-exclusion chromatography, co-immunoprecipitation, antibody internalization assays, deglycosylation experiments","journal":"BMC cell biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of functional sites combined with multiple biochemical assays (SEC, Co-IP, glycosylation mutants), single lab","pmids":["17565660"],"is_preprint":false},{"year":2007,"finding":"PPT1 deficiency leads to increased production of lysophosphatidylcholine (LPC), catalyzed by activation of cytosolic phospholipase A2 (cPLA2) in the PPT1-KO mouse brain. Age-dependent increases in LPC levels positively correlate with elevated expression of phagocyte-associated genes, identifying LPC as a 'lipid signal' for phagocyte recruitment contributing to INCL neuropathology.","method":"Lipid analysis of PPT1-KO mouse brain, cPLA2 activity assay, gene expression analysis, correlation of LPC levels with phagocyte markers","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical measurement of LPC and cPLA2 activity in KO model with gene expression correlation, single lab","pmids":["17341491"],"is_preprint":false},{"year":2008,"finding":"PPT1 interacts with the F1-complex of mitochondrial ATP synthase (identified by co-purification and in vitro-binding assays). In Ppt1-deficient neurons, the levels of F1-subunits α and β on the plasma membrane are specifically increased. Ppt1-deficiency is also associated with changes in apolipoprotein A-I uptake and altered serum lipid composition.","method":"Co-purification, in vitro binding assays, cell surface biotinylation, TIRF-microscopy, apolipoprotein A-I uptake assays in Ppt1Δex4 mice","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-purification plus in vitro binding assay, functional consequences in KO model, single lab","pmids":["18245779"],"is_preprint":false},{"year":2006,"finding":"PPT1 deficiency causes a defect in fluid-phase and receptor-mediated endocytosis (while marker uptake and recycling endocytosis remain intact), leading to hypersecretion and abnormal processing of prosaposin, resulting in accumulation of saposins A and D in PPT1-deficient fibroblasts and neurons.","method":"Endocytosis assays, metabolic labeling and immunoprecipitation of prosaposin, saposin localization by immunofluorescence in PPT1-deficient fibroblasts and mouse primary neurons","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays (endocytosis, metabolic labeling, IP), single lab, mechanistic pathway connection","pmids":["16542649"],"is_preprint":false},{"year":2015,"finding":"CSPα (encoded by DNAJC5/CLN4) is a substrate of PPT1; PPT1 depalmitoylates CSPα. In DNAJC5/CLN4 patient brains, PPT1 protein is massively increased but its specific enzymatic activity is dramatically reduced and it is mis-localized. Global changes in protein palmitoylation (primarily lysosomal and synaptic proteins) occur as a consequence of PPT1 accumulation without sufficient activity.","method":"Co-immunoprecipitation, quantitative palmitoylome proteomics from patient brains, enzymatic activity assays","journal":"Acta neuropathologica","confidence":"High","confidence_rationale":"Tier 1 / Moderate — enzymatic substrate identification with co-IP, quantitative proteomics of palmitoylome in patient tissue, multiple orthogonal methods","pmids":["26659577"],"is_preprint":false},{"year":2016,"finding":"PPT1 itself undergoes palmitoylation in vivo at cysteine-6, catalyzed by DHHC3 and DHHC7. Palmitoylation of PPT1 inhibits its depalmitoylation enzymatic activity (acts as a non-competitive inhibitor affecting Vmax) without affecting intracellular localization. The unpalmitoylated C6S mutant shows enhanced depalmitoylation activity, establishing a positive feedback loop where palmitoylation of PPT1 reduces its activity and increases substrate palmitoylation.","method":"Site-directed mutagenesis (C6S), in vitro and in vivo palmitoylation assays, DHHC enzyme co-expression, enzymatic kinetics (Vmax measurement), subcellular localization","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with enzymatic kinetics and in vivo palmitoylation assays, establishes both writer (DHHC3/7) and functional consequence","pmids":["26731412"],"is_preprint":false},{"year":2018,"finding":"PPT1 is the molecular target of chloroquine (CQ) derivatives including hydroxychloroquine (HCQ), Lys05, and dimeric CQ (DC661). Using photoaffinity pulldown, CQ derivatives were shown to bind and inhibit PPT1 enzymatic activity. CRISPR/Cas9 knockout of PPT1 in cancer cells abrogates autophagy modulation and cytotoxicity of CQ derivatives and significantly impairs tumor growth.","method":"In situ photoaffinity pulldown, enzymatic activity assays, CRISPR/Cas9 PPT1 knockout in cancer cells, tumor growth assays","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding by photoaffinity pulldown, enzyme inhibition assay, genetic validation by CRISPR KO, multiple orthogonal methods","pmids":["30442709"],"is_preprint":false},{"year":2019,"finding":"PPT1 is highly expressed in conventional type 1 dendritic cells (cDC1s) and promotes antigen degradation and endosomal acidification via V-ATPase recruitment, protecting DCs from viral infection. PPT1-deficient cDC1s show impaired response to VSV infection but enhanced priming of naive CD8+ T cells into KLRG1+ effectors and memory T cells. After DC activation, PPT1 is rapidly downregulated to facilitate cross-presentation.","method":"PPT1-deficient mouse models, VSV infection assays, T cell priming assays (in vivo), V-ATPase recruitment measurement, Listeria monocytogenes clearance assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function in specific cell type with defined mechanistic pathway (V-ATPase recruitment), multiple in vivo functional readouts","pmids":["31262842"],"is_preprint":false},{"year":2020,"finding":"PPT1 deficiency in Cln1-/- mice disrupts Rab7 S-palmitoylation-dependent trafficking to late endosomal/lysosomal membranes, preventing Rab7-RILP interaction and autophagosome-lysosome fusion, thereby impairing autophagic degradation. Treatment with NtBuHA (a PPT1-mimetic) ameliorated this defect.","method":"Autophagy flux assays in Cln1-/- mice and INCL patient fibroblasts, Rab7 palmitoylation assays, Rab7-RILP co-immunoprecipitation, NtBuHA rescue experiments","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for Rab7-RILP interaction, palmitoylation assays, functional rescue in KO model, single lab","pmids":["32279353"],"is_preprint":false},{"year":2021,"finding":"PPT1 depalmitoylates GFAP at cysteine-291, which is the unique palmitoylation site of GFAP. In PPT1-knockin mice, hyperpalmitoylated GFAP promotes astrocyte proliferation and astrogliosis. Blocking GFAP palmitoylation by mutating C291 to alanine attenuates astrogliosis and neurodegenerative pathology in PPT1-knockin mice.","method":"In vitro and in vivo palmitoylation assays, site-directed mutagenesis (C291A), astrocyte proliferation assays, histopathology of PPT1-KI mice","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — substrate identification with mutagenesis of palmitoylation site, functional rescue by mutation in disease model, multiple orthogonal methods","pmids":["33753498"],"is_preprint":false},{"year":2021,"finding":"PPT1 inhibition by GNS561 results in lysosomal unbound Zn2+ accumulation, impairment of cathepsin activity, blockage of autophagic flux, altered localization of mTOR, lysosomal membrane permeabilization, and caspase activation in hepatocellular carcinoma cells.","method":"PPT1 enzymatic activity assays, lysosomal Zn2+ measurement, cathepsin activity assays, autophagy flux assays, mTOR localization by immunofluorescence, in vivo HCC models","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PPT1 enzyme inhibition with multiple downstream functional readouts, in vivo validation, single lab","pmids":["34740311"],"is_preprint":false},{"year":2021,"finding":"In Cln1-/- mice (INCL model), PPT1-deficiency reduces ZDHHC5 and ZDHHC23 levels, which suppresses APT1 S-palmitoylation, causing increased membrane-localized H-Ras and activation of its proliferative signaling pathway in microglia, contributing to neuroinflammation.","method":"Western blot for ZDHHC5/ZDHHC23, APT1 palmitoylation assays, H-Ras membrane localization in Cln1-/- mouse brain, NtBuHA rescue treatment","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway identified in KO model with rescue, single lab, multiple biochemical readouts","pmids":["33739454"],"is_preprint":false},{"year":2024,"finding":"PPT1 mediates depalmitoylation of Gpx1 at cysteine-76 and cysteine-113, thereby negatively regulating Gpx1 protein stability. PPT1-regulated Gpx1 depalmitoylation promotes neovascular angiogenesis; in PPT1-deficient mice, angiogenesis is attenuated in the OIR model, and PPT1 inhibition with DC661 suppresses retinal angiogenesis.","method":"Palmitoylation assays (Gpx1 palmitoylation site mapping by mutagenesis), PPT1-deficient mouse OIR model, angiogenesis assays, DC661 pharmacological inhibition","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate identification (Gpx1) with mutagenesis, in vivo disease model, pharmacological and genetic validation, single lab","pmids":["39423458"],"is_preprint":false},{"year":2002,"finding":"Lipid-cysteine thioesters (substrates for PPT1) accumulate in the lysosomal fraction of PPT1-deficient cells, and their appearance is blocked by inhibitors of lysosomal proteolysis (leupeptin, chloroquine). These substrates also accumulate in normal cells after leupeptin or chloroquine treatment, demonstrating through biochemical fractionation that PPT1 acts in the lysosome to remove fatty acids from proteins undergoing lysosomal degradation.","method":"Biochemical cell fractionation, [35S]cysteine metabolic labeling, lysosomal inhibitor treatment (leupeptin, chloroquine, cysteamine), organic phase extraction and analysis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct biochemical demonstration of lysosomal substrate accumulation using multiple inhibitors and fractionation, mechanistically establishes site of PPT1 action","pmids":["12069847"],"is_preprint":false},{"year":2003,"finding":"Over-expression of DmPpt1 (Drosophila Ppt1 ortholog) in the developing visual system leads to cell loss through apoptotic cell death. Over-expression of the catalytic site mutant DmPpt1-S123A does not cause the eye phenotype, demonstrating that cell loss depends on the catalytic activity of PPT1.","method":"Drosophila transgenic over-expression system, active-site serine-to-alanine mutagenesis (S123A), eye morphology phenotype analysis, genetic deficiency suppression","journal":"BMC neuroscience","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — catalytic site mutagenesis in Drosophila model with defined phenotypic readout, demonstrates catalytic activity required for function","pmids":["14629778"],"is_preprint":false},{"year":2019,"finding":"CLN3 mutations suppress the exit of cation-independent mannose-6-phosphate receptor (CI-M6PR) from the trans-Golgi network, reducing lysosomal PPT1 protein levels and PPT1 enzymatic activity in Cln3-mutant mice and JNCL patient cells. This establishes a pathway linking CLN3 function to lysosomal PPT1 delivery via CI-M6PR trafficking.","method":"Lysosomal fractionation and PPT1 enzymatic activity measurement in Cln3 mutant mice and JNCL patient fibroblasts, V0a1 v-ATPase subunit localization","journal":"Journal of inherited metabolic disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzymatic activity and protein level measurements in KO model and patient cells, pathway epistasis via CI-M6PR, single lab","pmids":["31025705"],"is_preprint":false},{"year":2015,"finding":"PPT1 deficiency in Cln1-/- mice impairs the proteolytic processing of cathepsin D (CLN10/CD) precursor to its enzymatically active form in the lysosome, despite Cln10 overexpression, thereby impairing lysosomal degradative function. Treatment with NtBuHA ameliorated the cathepsin D processing defect.","method":"Western blot for cathepsin D maturation in Cln1-/- mouse brain and cultured brain cells, enzymatic activity assays, confocal microscopy, NtBuHA rescue treatment","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical demonstration of CD maturation defect with functional rescue, single lab, multiple readouts","pmids":["26160911"],"is_preprint":false}],"current_model":"PPT1 (palmitoyl-protein thioesterase 1) is a lysosomal serine hydrolase that removes palmitate from S-acylated cysteine residues on proteins undergoing lysosomal degradation; it localizes to lysosomes in non-neuronal cells but also to synaptosomes and synaptic vesicles in neurons, requires N-glycosylation at N197/N232 for activity and transport, forms oligomeric complexes, is itself palmitoylated by DHHC3/7 (which inhibits its activity via a feedback loop), depalmitoylates substrates including GAP-43, GFAP (at C291), CSPα, Rab7, and Gpx1 to regulate their stability/trafficking, promotes endosomal acidification and V-ATPase recruitment in dendritic cells, and its deficiency triggers ER stress/UPR, impairs autophagosome-lysosome fusion via Rab7-RILP disruption, dysregulates cathepsin D maturation, and activates caspase cascades leading to neurodegeneration in infantile neuronal ceroid lipofuscinosis (INCL/CLN1 disease); pharmacologically, it is the direct molecular target of chloroquine derivatives used as autophagy inhibitors in cancer."},"narrative":{"mechanistic_narrative":"PPT1 is a ubiquitously expressed glycoprotein thioesterase that removes palmitate from S-acylated cysteine residues on proteins undergoing lysosomal degradation, and its loss causes infantile neuronal ceroid lipofuscinosis (INCL/CLN1 disease) [PMID:8786130, PMID:11717424, PMID:12069847]. Biochemical fractionation localizes its catalytic action to the lysosome, where it depalmitoylates substrate proteins en route to degradation, while in neurons the enzyme is additionally found at synaptosomes and synaptic vesicles and is routed via the mannose-6-phosphate receptor [PMID:11136716, PMID:12069847]. Crystallographic comparison with PPT2 attributes its ability to act on palmitoylated proteins to a solvent-exposed lipid-binding groove [PMID:12855696], and N-glycosylation at N197/N232 plus oligomerization are required for activity and trafficking [PMID:17565660]. Catalytic activity is functionally essential, as catalytically dead enzyme fails to reproduce gain-of-function phenotypes [PMID:14629778], and the enzyme is itself palmitoylated at cysteine-6 by DHHC3/DHHC7, which non-competitively inhibits its activity in a feedback loop [PMID:26731412]. Identified substrates whose stability and trafficking it controls include CSPα, Rab7, GFAP (at C291), and Gpx1 (at C76/C113) [PMID:26659577, PMID:32279353, PMID:33753498, PMID:39423458]. PPT1 deficiency triggers ER stress and the unfolded protein response with downstream caspase activation and neuronal apoptosis, disrupts Rab7-RILP-dependent autophagosome-lysosome fusion, and impairs cathepsin D maturation, collectively driving neurodegeneration [PMID:16368712, PMID:16644870, PMID:32279353, PMID:26160911]. Beyond its disease role, PPT1 promotes endosomal acidification via V-ATPase recruitment in dendritic cells [PMID:31262842] and is the direct molecular target of chloroquine-derivative autophagy inhibitors used against cancer [PMID:30442709].","teleology":[{"year":1996,"claim":"Established the molecular identity of PPT1 as a glycosylated thioesterase that removes palmitate from lipid-modified cysteine residues, defining the enzyme to be characterized.","evidence":"cDNA/genomic cloning, sequence analysis, and Northern blot showing ubiquitous 2.5-kb transcript","pmids":["8786130"],"confidence":"High","gaps":["Physiological substrates not yet identified","Subcellular site of action not yet established"]},{"year":2001,"claim":"Linked PPT1 loss to a defined neurodegenerative disease, showing the enzyme is deficient in INCL and acts on cysteine-modified proteins undergoing lysosomal degradation.","evidence":"PPT1 knockout mouse with INCL-like neuropathology plus enzymatic assays","pmids":["11717424"],"confidence":"High","gaps":["Specific disease-driving substrates undefined","Molecular cascade from enzyme loss to apoptosis unresolved"]},{"year":2001,"claim":"Resolved the cell-type-specific routing of PPT1, distinguishing classical M6PR-dependent lysosomal targeting in non-neuronal cells from synaptic localization in neurons.","evidence":"Confocal/cryo-IEM, fractionation, and M6PR binding across neuronal, COS-1, and polarized epithelial cells","pmids":["11136716"],"confidence":"High","gaps":["Mechanism directing neuronal synaptic localization unclear","Functional role at synaptic vesicles undefined"]},{"year":2002,"claim":"Demonstrated that PPT1 acts within the lysosome to remove fatty acids from proteins during degradation, fixing the site of catalytic action.","evidence":"Biochemical fractionation with [35S]cysteine labeling and lysosomal protease/acidification inhibitors","pmids":["12069847"],"confidence":"High","gaps":["Identity of accumulating thioester substrates not defined","Does not address extralysosomal neuronal pools"]},{"year":2003,"claim":"Provided the structural basis for PPT1's substrate specificity, explaining why it acts on palmitoylated proteins whereas PPT2 prefers unbranched acyl-CoA.","evidence":"X-ray crystallography of PPT2, structural comparison with PPT1, and in vitro substrate specificity assays","pmids":["12855696"],"confidence":"High","gaps":["No co-crystal with a protein substrate","Catalytic mechanism detail on intact proteins untested"]},{"year":2003,"claim":"Showed that PPT1 function in vivo depends on its catalytic activity, ruling out a purely structural role.","evidence":"Drosophila over-expression of wild-type vs. catalytic-mutant (S123A) DmPpt1 with eye phenotype readout","pmids":["14629778"],"confidence":"Medium","gaps":["Over-expression phenotype not directly equivalent to loss-of-function disease","Mammalian substrate relevance not addressed"]},{"year":2005,"claim":"Defined a death pathway downstream of PPT1 loss: ER accumulation of palmitoylated GAP-43 triggers UPR and caspase-mediated neuronal apoptosis.","evidence":"PPT1-KO mouse brain and GFP-GAP-43 expression with UPR/caspase Western blots","pmids":["16368712"],"confidence":"High","gaps":["GAP-43 causal contribution to disease not proven by rescue","Other accumulating substrates not enumerated"]},{"year":2006,"claim":"Extended the apoptotic mechanism to human INCL and to additional death branches (oxidative/mitochondrial), confirming caspase-driven neurodegeneration.","evidence":"Human INCL cells with caspase-4 inhibition rescue; KO brain/neurosphere ROS, SOD-2, caspase-9/3, PARP measurements","pmids":["16644870","16571600"],"confidence":"High","gaps":["Relative contribution of ER-stress vs. mitochondrial pathways unquantified","Caspase-9 pathway placement by correlation, not rescue"]},{"year":2006,"claim":"Connected PPT1 loss to broader lysosomal/endocytic dysfunction by showing impaired endocytosis and aberrant prosaposin processing.","evidence":"Endocytosis assays, metabolic labeling/IP of prosaposin, and saposin localization in PPT1-deficient fibroblasts and neurons","pmids":["16542649"],"confidence":"Medium","gaps":["Direct molecular link between PPT1 activity and endocytic machinery unidentified","Single-lab finding"]},{"year":2007,"claim":"Defined post-translational and assembly requirements for PPT1, showing N197/N232 glycosylation and oligomerization are needed for activity and trafficking.","evidence":"Site-directed mutagenesis of glycosylation sites, SEC, co-IP, and deglycosylation experiments","pmids":["17565660"],"confidence":"High","gaps":["Structural basis of oligomerization not resolved","Why disease mutants hyperglycosylate unclear"]},{"year":2007,"claim":"Identified a lipid-signaling consequence of PPT1 loss linking enzyme deficiency to phagocyte-driven neuroinflammation via LPC accumulation.","evidence":"Brain lipid analysis, cPLA2 activity, and gene expression correlation in PPT1-KO mice","pmids":["17341491"],"confidence":"Medium","gaps":["cPLA2 activation mechanism downstream of PPT1 loss undefined","Causal role of LPC in pathology shown only by correlation"]},{"year":2008,"claim":"Reported a non-canonical PPT1 interaction with mitochondrial ATP synthase F1-complex and altered lipoprotein handling, broadening its functional context.","evidence":"Co-purification, in vitro binding, cell-surface biotinylation/TIRF, and ApoA-I uptake assays in Ppt1-deficient mice","pmids":["18245779"],"confidence":"Medium","gaps":["Functional significance of the F1-complex interaction unresolved","Single co-purification without reciprocal validation"]},{"year":2015,"claim":"Began identifying specific physiological substrates and processing roles: CSPα as a PPT1 substrate and cathepsin D maturation dependence on PPT1.","evidence":"Co-IP and palmitoylome proteomics from DNAJC5/CLN4 patient brains; cathepsin D maturation Westerns with NtBuHA rescue in Cln1-/- mice","pmids":["26659577","26160911"],"confidence":"High","gaps":["Mechanism by which PPT1 controls cathepsin D processing indirect","Causality between palmitoylome shifts and disease not fully resolved"]},{"year":2016,"claim":"Revealed autoregulation: PPT1 is palmitoylated at Cys6 by DHHC3/7, which non-competitively inhibits its activity, establishing a feedback loop controlling global palmitoylation.","evidence":"C6S mutagenesis, in vitro/in vivo palmitoylation assays, DHHC co-expression, and enzyme kinetics","pmids":["26731412"],"confidence":"High","gaps":["Physiological conditions regulating PPT1 palmitoylation unknown","Impact on disease progression untested"]},{"year":2018,"claim":"Identified PPT1 as the direct molecular target of chloroquine-derivative autophagy inhibitors, repurposing it as an anticancer drug target.","evidence":"In situ photoaffinity pulldown, enzyme inhibition assays, and CRISPR PPT1 knockout with tumor growth assays","pmids":["30442709"],"confidence":"High","gaps":["Binding-site structural detail not resolved","Substrate(s) mediating the autophagy-modulating effect undefined"]},{"year":2019,"claim":"Defined a cell-type-specific physiological role in dendritic cells, where PPT1 drives V-ATPase-dependent endosomal acidification and antigen degradation, balancing antiviral defense against T cell priming.","evidence":"PPT1-deficient mice, VSV infection, in vivo T cell priming, V-ATPase recruitment, and Listeria clearance assays","pmids":["31262842"],"confidence":"High","gaps":["Direct V-ATPase substrate/palmitoylation link not defined","Relationship to neuronal PPT1 function unclear"]},{"year":2019,"claim":"Placed PPT1 in the broader NCL network by showing CLN3 controls lysosomal PPT1 delivery via CI-M6PR trafficking.","evidence":"Lysosomal fractionation and PPT1 activity in Cln3-mutant mice and JNCL patient cells","pmids":["31025705"],"confidence":"Medium","gaps":["Direct CLN3-CI-M6PR mechanism not fully resolved","Single-lab epistasis"]},{"year":2020,"claim":"Mechanistically linked PPT1 loss to autophagy failure through defective Rab7 palmitoylation, blocking Rab7-RILP interaction and autophagosome-lysosome fusion.","evidence":"Autophagy flux, Rab7 palmitoylation, Rab7-RILP co-IP, and NtBuHA rescue in Cln1-/- mice and patient fibroblasts","pmids":["32279353"],"confidence":"Medium","gaps":["Direct demonstration that Rab7 is a PPT1 catalytic substrate incomplete","Single-lab finding"]},{"year":2021,"claim":"Expanded the substrate repertoire and disease mechanism through GFAP (C291) depalmitoylation controlling astrogliosis, and a microglial ZDHHC/APT1/H-Ras axis driving neuroinflammation.","evidence":"Palmitoylation assays and C291A mutagenesis in PPT1-knockin mice; ZDHHC5/23, APT1 palmitoylation, and H-Ras localization with NtBuHA rescue in Cln1-/- mice","pmids":["33753498","33739454"],"confidence":"High","gaps":["GFAP/H-Ras contributions to overall disease severity not quantified","Microglial axis is single-lab"]},{"year":2021,"claim":"Characterized the downstream lysosomal consequences of pharmacological PPT1 inhibition in cancer: Zn2+ accumulation, cathepsin impairment, autophagy blockade, and lysosomal membrane permeabilization.","evidence":"GNS561 PPT1 inhibition with lysosomal Zn2+, cathepsin, autophagy flux, mTOR localization, and in vivo HCC assays","pmids":["34740311"],"confidence":"Medium","gaps":["Direct PPT1 substrate mediating these effects undefined","Single-lab finding"]},{"year":2024,"claim":"Added Gpx1 (C76/C113) as a PPT1 substrate whose depalmitoylation destabilizes the protein and drives neovascular angiogenesis, extending PPT1 function beyond neurodegeneration.","evidence":"Gpx1 palmitoylation-site mapping, PPT1-deficient OIR mouse model, and DC661 inhibition in angiogenesis assays","pmids":["39423458"],"confidence":"Medium","gaps":["Tissue specificity of Gpx1 regulation unclear","Single-lab finding"]},{"year":null,"claim":"How PPT1 substrate selection is governed in different compartments (lysosome vs. synapse vs. endosome) and which specific depalmitoylation events are causally rate-limiting for INCL and for cancer drug response remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking individual substrate effects to disease severity","Structural basis of inhibitor and substrate binding incomplete","Mechanism of neuronal non-lysosomal targeting unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,11,16,19,20]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,3,20]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[2,20,22]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[10,14]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[13,15,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,4,5,22]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[11,16,19]}],"complexes":[],"partners":["DHHC3","DHHC7","RAB7","RILP","CSPALPHA","GFAP","GPX1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P50897","full_name":"Palmitoyl-protein thioesterase 1","aliases":["Palmitoyl-protein hydrolase 1"],"length_aa":306,"mass_kda":34.2,"function":"Has thioesterase activity against fatty acid thioesters with 14 -18 carbons, including palmitoyl-CoA, S-palmitoyl-N-acetylcysteamine, and palmitoylated proteins (PubMed:12855696, PubMed:26731412, PubMed:8816748). In contrast to PPT2, PPT1 can hydrolyze palmitoylated proteins and palmitoylcysteine (PubMed:12855696)","subcellular_location":"Lysosome; Secreted; Golgi apparatus; Endoplasmic reticulum","url":"https://www.uniprot.org/uniprotkb/P50897/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PPT1","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":4.0}],"url":"https://opencell.sf.czbiohub.org/search/PPT1","total_profiled":1310},"omim":[{"mim_id":"606725","title":"CLN6 TRANSMEMBRANE ER PROTEIN; CLN6","url":"https://www.omim.org/entry/606725"},{"mim_id":"605489","title":"INTRAFLAGELLAR TRANSPORT 81; IFT81","url":"https://www.omim.org/entry/605489"},{"mim_id":"603298","title":"PALMITOYL-PROTEIN THIOESTERASE 2; PPT2","url":"https://www.omim.org/entry/603298"},{"mim_id":"600722","title":"PALMITOYL-PROTEIN THIOESTERASE 1; PPT1","url":"https://www.omim.org/entry/600722"},{"mim_id":"600658","title":"PROTEIN PHOSPHATASE 5, CATALYTIC SUBUNIT; PPP5C","url":"https://www.omim.org/entry/600658"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Golgi apparatus","reliability":"Supported"},{"location":"Vesicles","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PPT1"},"hgnc":{"alias_symbol":["CLN1","INCL"],"prev_symbol":["PPT"]},"alphafold":{"accession":"P50897","domains":[{"cath_id":"3.40.50.1820","chopping":"36-146_214-305","consensus_level":"high","plddt":97.9159,"start":36,"end":305}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50897","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50897-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50897-F1-predicted_aligned_error_v6.png","plddt_mean":91.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PPT1","jax_strain_url":"https://www.jax.org/strain/search?query=PPT1"},"sequence":{"accession":"P50897","fasta_url":"https://rest.uniprot.org/uniprotkb/P50897.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50897/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50897"}},"corpus_meta":[{"pmid":"8387915","id":"PMC_8387915","title":"Comparison of the Saccharomyces cerevisiae G1 cyclins: Cln3 may be an upstream activator of Cln1, Cln2 and other cyclins.","date":"1993","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8387915","citation_count":429,"is_preprint":false},{"pmid":"12676324","id":"PMC_12676324","title":"The role of Ppt/Wnt5 in regulating cell shape and movement during zebrafish gastrulation.","date":"2003","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/12676324","citation_count":262,"is_preprint":false},{"pmid":"11717424","id":"PMC_11717424","title":"Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11717424","citation_count":257,"is_preprint":false},{"pmid":"30442709","id":"PMC_30442709","title":"PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer.","date":"2018","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/30442709","citation_count":202,"is_preprint":false},{"pmid":"1946350","id":"PMC_1946350","title":"FUS3 represses CLN1 and CLN2 and in concert with KSS1 promotes signal transduction.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1946350","citation_count":192,"is_preprint":false},{"pmid":"8262070","id":"PMC_8262070","title":"Yeast G1 cyclins CLN1 and CLN2 and a GAP-like protein have a role in bud formation.","date":"1993","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8262070","citation_count":151,"is_preprint":false},{"pmid":"1334024","id":"PMC_1334024","title":"SIT4 protein phosphatase is required for the normal accumulation of SWI4, CLN1, CLN2, and HCS26 RNAs during late G1.","date":"1992","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1334024","citation_count":135,"is_preprint":false},{"pmid":"16407978","id":"PMC_16407978","title":"The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16407978","citation_count":128,"is_preprint":false},{"pmid":"16644870","id":"PMC_16644870","title":"Endoplasmic reticulum stress-induced caspase-4 activation mediates apoptosis and neurodegeneration in INCL.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16644870","citation_count":127,"is_preprint":false},{"pmid":"9367985","id":"PMC_9367985","title":"Rad53-dependent phosphorylation of Swi6 and down-regulation of CLN1 and CLN2 transcription occur in response to DNA damage in Saccharomyces cerevisiae.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9367985","citation_count":125,"is_preprint":false},{"pmid":"9425237","id":"PMC_9425237","title":"Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits.","date":"1998","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9425237","citation_count":113,"is_preprint":false},{"pmid":"10191108","id":"PMC_10191108","title":"A rapid fluorogenic palmitoyl-protein thioesterase assay: pre- and postnatal diagnosis of INCL.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191108","citation_count":108,"is_preprint":false},{"pmid":"7926787","id":"PMC_7926787","title":"G1 cyclins CLN1 and CLN2 repress the mating factor response pathway at Start in the yeast cell cycle.","date":"1994","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/7926787","citation_count":107,"is_preprint":false},{"pmid":"9835490","id":"PMC_9835490","title":"Class 1 integron-borne multiple-antibiotic resistance carried by IncFI and IncL/M plasmids in Salmonella enterica serotype typhimurium.","date":"1998","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/9835490","citation_count":106,"is_preprint":false},{"pmid":"16368712","id":"PMC_16368712","title":"Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16368712","citation_count":101,"is_preprint":false},{"pmid":"11136716","id":"PMC_11136716","title":"Palmitoyl protein thioesterase (PPT) localizes into synaptosomes and synaptic vesicles in neurons: implications for infantile neuronal ceroid lipofuscinosis (INCL).","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11136716","citation_count":97,"is_preprint":false},{"pmid":"34740311","id":"PMC_34740311","title":"GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34740311","citation_count":82,"is_preprint":false},{"pmid":"30876460","id":"PMC_30876460","title":"Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30876460","citation_count":78,"is_preprint":false},{"pmid":"32780726","id":"PMC_32780726","title":"PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32780726","citation_count":75,"is_preprint":false},{"pmid":"26659577","id":"PMC_26659577","title":"Neuronal ceroid lipofuscinosis with DNAJC5/CSPα mutation has PPT1 pathology and exhibit aberrant protein palmitoylation.","date":"2015","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/26659577","citation_count":69,"is_preprint":false},{"pmid":"24056696","id":"PMC_24056696","title":"Neuroprotection and lifespan extension in Ppt1(-/-) mice by NtBuHA: therapeutic implications for INCL.","date":"2013","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24056696","citation_count":68,"is_preprint":false},{"pmid":"15649713","id":"PMC_15649713","title":"Mice with Ppt1Deltaex4 mutation replicate the INCL phenotype and show an inflammation-associated loss of interneurons.","date":"2005","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/15649713","citation_count":66,"is_preprint":false},{"pmid":"7705654","id":"PMC_7705654","title":"Overexpression of SIS2, which contains an extremely acidic region, increases the expression of SWI4, CLN1 and CLN2 in sit4 mutants.","date":"1995","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7705654","citation_count":66,"is_preprint":false},{"pmid":"32963323","id":"PMC_32963323","title":"Highly efficient gene transfer in the mouse gut microbiota is enabled by the Incl2 conjugative plasmid TP114.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32963323","citation_count":62,"is_preprint":false},{"pmid":"20494602","id":"PMC_20494602","title":"A mutation in canine PPT1 causes early onset neuronal ceroid lipofuscinosis in a Dachshund.","date":"2010","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20494602","citation_count":60,"is_preprint":false},{"pmid":"17916570","id":"PMC_17916570","title":"PPT-DB: the protein property prediction and testing database.","date":"2007","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/17916570","citation_count":58,"is_preprint":false},{"pmid":"18245779","id":"PMC_18245779","title":"Deficiency of the INCL protein Ppt1 results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18245779","citation_count":57,"is_preprint":false},{"pmid":"24752261","id":"PMC_24752261","title":"IS1R-mediated plasticity of IncL/M plasmids leads to the insertion of bla OXA-48 into the Escherichia coli Chromosome.","date":"2014","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/24752261","citation_count":57,"is_preprint":false},{"pmid":"28673981","id":"PMC_28673981","title":"Synergistic effects of treating the spinal cord and brain in CLN1 disease.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28673981","citation_count":55,"is_preprint":false},{"pmid":"16571600","id":"PMC_16571600","title":"Palmitoyl-protein thioesterase-1 deficiency leads to the activation of caspase-9 and contributes to rapid neurodegeneration in INCL.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16571600","citation_count":53,"is_preprint":false},{"pmid":"19281799","id":"PMC_19281799","title":"Divergent effects of estradiol and the estrogen receptor-alpha agonist PPT on eating and activation of PVN CRH neurons in ovariectomized rats and mice.","date":"2009","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/19281799","citation_count":53,"is_preprint":false},{"pmid":"10477428","id":"PMC_10477428","title":"Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5.","date":"1999","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10477428","citation_count":50,"is_preprint":false},{"pmid":"12855696","id":"PMC_12855696","title":"The crystal structure of palmitoyl protein thioesterase-2 (PPT2) reveals the basis for divergent substrate specificities of the two lysosomal thioesterases, PPT1 and PPT2.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12855696","citation_count":50,"is_preprint":false},{"pmid":"9737966","id":"PMC_9737966","title":"Potential regulation of Ste20 function by the Cln1-Cdc28 and Cln2-Cdc28 cyclin-dependent protein kinases.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9737966","citation_count":48,"is_preprint":false},{"pmid":"25205113","id":"PMC_25205113","title":"The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25205113","citation_count":48,"is_preprint":false},{"pmid":"33753498","id":"PMC_33753498","title":"GFAP hyperpalmitoylation exacerbates astrogliosis and neurodegenerative pathology in PPT1-deficient mice.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33753498","citation_count":47,"is_preprint":false},{"pmid":"7563090","id":"PMC_7563090","title":"Plus-strand DNA synthesis of the yeast retrotransposon Ty1 is initiated at two sites, PPT1 next to the 3' LTR and PPT2 within the pol gene. PPT1 is sufficient for Ty1 transposition.","date":"1995","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7563090","citation_count":47,"is_preprint":false},{"pmid":"21704547","id":"PMC_21704547","title":"Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients.","date":"2011","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21704547","citation_count":47,"is_preprint":false},{"pmid":"9083033","id":"PMC_9083033","title":"Cell cycle-dependent transcription of CLN1 involves swi4 binding to MCB-like elements.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9083033","citation_count":45,"is_preprint":false},{"pmid":"37385725","id":"PMC_37385725","title":"Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37385725","citation_count":44,"is_preprint":false},{"pmid":"9566870","id":"PMC_9566870","title":"Regulation of cell size by glucose is exerted via repression of the CLN1 promoter.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9566870","citation_count":44,"is_preprint":false},{"pmid":"10611226","id":"PMC_10611226","title":"CLN1 and its repression by Xbp1 are important for efficient sporulation in budding yeast.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10611226","citation_count":42,"is_preprint":false},{"pmid":"31736929","id":"PMC_31736929","title":"Pathogenicity of Clinical OXA-48 Isolates and Impact of the OXA-48 IncL Plasmid on Virulence and Bacterial Fitness.","date":"2019","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31736929","citation_count":42,"is_preprint":false},{"pmid":"21224254","id":"PMC_21224254","title":"Disruption of adaptive energy metabolism and elevated ribosomal p-S6K1 levels contribute to INCL pathogenesis: partial rescue by resveratrol.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21224254","citation_count":41,"is_preprint":false},{"pmid":"11020216","id":"PMC_11020216","title":"Antisense palmitoyl protein thioesterase 1 (PPT1) treatment inhibits PPT1 activity and increases cell death in LA-N-5 neuroblastoma cells.","date":"2000","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/11020216","citation_count":40,"is_preprint":false},{"pmid":"22310926","id":"PMC_22310926","title":"Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis.","date":"2012","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/22310926","citation_count":40,"is_preprint":false},{"pmid":"31289301","id":"PMC_31289301","title":"CRISPR/Cas9 mediated generation of an ovine model for infantile neuronal ceroid lipofuscinosis (CLN1 disease).","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31289301","citation_count":40,"is_preprint":false},{"pmid":"20561933","id":"PMC_20561933","title":"Omega-3 and omega-6 fatty acids suppress ER- and oxidative stress in cultured neurons and neuronal progenitor cells from mice lacking PPT1.","date":"2010","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/20561933","citation_count":40,"is_preprint":false},{"pmid":"17656100","id":"PMC_17656100","title":"Palmitoyl protein thioesterase 1 (Ppt1)-deficient mouse neurons show alterations in cholesterol metabolism and calcium homeostasis prior to synaptic dysfunction.","date":"2007","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/17656100","citation_count":39,"is_preprint":false},{"pmid":"20036592","id":"PMC_20036592","title":"Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis.","date":"2009","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20036592","citation_count":38,"is_preprint":false},{"pmid":"17341491","id":"PMC_17341491","title":"Production of lysophosphatidylcholine by cPLA2 in the brain of mice lacking PPT1 is a signal for phagocyte infiltration.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17341491","citation_count":38,"is_preprint":false},{"pmid":"23747979","id":"PMC_23747979","title":"Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23747979","citation_count":36,"is_preprint":false},{"pmid":"31262842","id":"PMC_31262842","title":"Thioesterase PPT1 balances viral resistance and efficient T cell crosspriming in dendritic cells.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31262842","citation_count":35,"is_preprint":false},{"pmid":"17565660","id":"PMC_17565660","title":"Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1)--distinct characteristics in neurons.","date":"2007","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17565660","citation_count":34,"is_preprint":false},{"pmid":"14629778","id":"PMC_14629778","title":"An over-expression system for characterizing Ppt1 function in Drosophila.","date":"2003","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/14629778","citation_count":33,"is_preprint":false},{"pmid":"20346914","id":"PMC_20346914","title":"Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20346914","citation_count":33,"is_preprint":false},{"pmid":"9219335","id":"PMC_9219335","title":"Deregulation of CLN1 and CLN2 in the Saccharomyces cerevisiae whi2 mutant.","date":"1997","source":"Yeast (Chichester, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9219335","citation_count":32,"is_preprint":false},{"pmid":"26731412","id":"PMC_26731412","title":"Reversible Cysteine Acylation Regulates the Activity of Human Palmitoyl-Protein Thioesterase 1 (PPT1).","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26731412","citation_count":32,"is_preprint":false},{"pmid":"16542649","id":"PMC_16542649","title":"Palmitoyl protein thioesterase 1 (PPT1) deficiency causes endocytic defects connected to abnormal saposin processing.","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16542649","citation_count":31,"is_preprint":false},{"pmid":"12125808","id":"PMC_12125808","title":"Neuronal ceroid lipofuscinoses caused by defects in soluble lysosomal enzymes (CLN1 and CLN2).","date":"2002","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12125808","citation_count":31,"is_preprint":false},{"pmid":"26707855","id":"PMC_26707855","title":"Proteomic Profiling in the Brain of CLN1 Disease Model Reveals Affected Functional Modules.","date":"2015","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26707855","citation_count":31,"is_preprint":false},{"pmid":"7789974","id":"PMC_7789974","title":"Identification of YAC clones for human chromosome 1p32 and physical mapping of the infantile neuronal ceroid lipofuscinosis (INCL) locus.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7789974","citation_count":31,"is_preprint":false},{"pmid":"34000449","id":"PMC_34000449","title":"Management of CLN1 Disease: International Clinical Consensus.","date":"2021","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34000449","citation_count":30,"is_preprint":false},{"pmid":"18493058","id":"PMC_18493058","title":"Ccr4 alters cell size in yeast by modulating the timing of CLN1 and CLN2 expression.","date":"2008","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18493058","citation_count":30,"is_preprint":false},{"pmid":"29631617","id":"PMC_29631617","title":"Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses.","date":"2018","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29631617","citation_count":28,"is_preprint":false},{"pmid":"34634930","id":"PMC_34634930","title":"The Cyclin Cln1 Controls Polyploid Titan Cell Formation following a Stress-Induced G2 Arrest in Cryptococcus.","date":"2021","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/34634930","citation_count":28,"is_preprint":false},{"pmid":"26082752","id":"PMC_26082752","title":"Orexin Receptor Activation Generates Gamma Band Input to Cholinergic and Serotonergic Arousal System Neurons and Drives an Intrinsic Ca(2+)-Dependent Resonance in LDT and PPT Cholinergic Neurons.","date":"2015","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26082752","citation_count":28,"is_preprint":false},{"pmid":"35949290","id":"PMC_35949290","title":"First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.","date":"2022","source":"Liver cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35949290","citation_count":28,"is_preprint":false},{"pmid":"28008682","id":"PMC_28008682","title":"Homozygous PPT1 Splice Donor Mutation in a Cane Corso Dog With Neuronal Ceroid Lipofuscinosis.","date":"2016","source":"Journal of veterinary internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28008682","citation_count":28,"is_preprint":false},{"pmid":"31035240","id":"PMC_31035240","title":"InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.","date":"2019","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31035240","citation_count":27,"is_preprint":false},{"pmid":"7543895","id":"PMC_7543895","title":"The replication of an IncL/M plasmid is subject to antisense control.","date":"1995","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/7543895","citation_count":27,"is_preprint":false},{"pmid":"8786130","id":"PMC_8786130","title":"cDNA and genomic cloning of human palmitoyl-protein thioesterase (PPT), the enzyme defective in infantile neuronal ceroid lipofuscinosis.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8786130","citation_count":27,"is_preprint":false},{"pmid":"35004674","id":"PMC_35004674","title":"PPT1 Reduction Contributes to Erianin-Induced Growth Inhibition in Oral Squamous Carcinoma Cells.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35004674","citation_count":26,"is_preprint":false},{"pmid":"25437009","id":"PMC_25437009","title":"Expanding access to HIV viral load testing: a systematic review of RNA stability in EDTA tubes and PPT beyond current time and temperature thresholds.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25437009","citation_count":26,"is_preprint":false},{"pmid":"30548340","id":"PMC_30548340","title":"Astrocyte-targeted IL-10 production decreases proliferation and induces a downregulation of activated microglia/macrophages after PPT.","date":"2018","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/30548340","citation_count":26,"is_preprint":false},{"pmid":"10874636","id":"PMC_10874636","title":"A new simple enzyme assay for pre- and postnatal diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) and its variants.","date":"1999","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10874636","citation_count":25,"is_preprint":false},{"pmid":"11001812","id":"PMC_11001812","title":"Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3.","date":"2000","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11001812","citation_count":24,"is_preprint":false},{"pmid":"35758669","id":"PMC_35758669","title":"Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration.","date":"2022","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/35758669","citation_count":24,"is_preprint":false},{"pmid":"33115477","id":"PMC_33115477","title":"Sex- and region-biased depletion of microglia/macrophages attenuates CLN1 disease in mice.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/33115477","citation_count":24,"is_preprint":false},{"pmid":"33739454","id":"PMC_33739454","title":"In a mouse model of INCL reduced S-palmitoylation of cytosolic thioesterase APT1 contributes to microglia proliferation and neuroinflammation.","date":"2021","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/33739454","citation_count":24,"is_preprint":false},{"pmid":"25574475","id":"PMC_25574475","title":"Mice homozygous for c.451C>T mutation in Cln1 gene recapitulate INCL phenotype.","date":"2014","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25574475","citation_count":23,"is_preprint":false},{"pmid":"23065637","id":"PMC_23065637","title":"Exacerbated neuronal ceroid lipofuscinosis phenotype in Cln1/5 double-knockout mice.","date":"2012","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/23065637","citation_count":22,"is_preprint":false},{"pmid":"26648046","id":"PMC_26648046","title":"Tissue-specific variation in nonsense mutant transcript level and drug-induced read-through efficiency in the Cln1(R151X) mouse model of INCL.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26648046","citation_count":22,"is_preprint":false},{"pmid":"26160911","id":"PMC_26160911","title":"Cln1 gene disruption in mice reveals a common pathogenic link between two of the most lethal childhood neurodegenerative lysosomal storage disorders.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26160911","citation_count":22,"is_preprint":false},{"pmid":"1680233","id":"PMC_1680233","title":"DNA-based prenatal diagnosis of the infantile form of neuronal ceroid lipofuscinosis (INCL, CLN1).","date":"1991","source":"Prenatal diagnosis","url":"https://pubmed.ncbi.nlm.nih.gov/1680233","citation_count":22,"is_preprint":false},{"pmid":"12069847","id":"PMC_12069847","title":"The effects of lysosomotropic agents on normal and INCL cells provide further evidence for the lysosomal nature of palmitoyl-protein thioesterase function.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12069847","citation_count":22,"is_preprint":false},{"pmid":"32841420","id":"PMC_32841420","title":"Spinal manifestations of CLN1 disease start during the early postnatal period.","date":"2020","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/32841420","citation_count":21,"is_preprint":false},{"pmid":"35628400","id":"PMC_35628400","title":"Seizures in PPT1 Knock-In Mice Are Associated with Inflammatory Activation of Microglia.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35628400","citation_count":21,"is_preprint":false},{"pmid":"32189079","id":"PMC_32189079","title":"Quantitative γ-H2AX immunofluorescence method for DNA double-strand break analysis in testis and liver after intravenous administration of 111InCl3.","date":"2020","source":"EJNMMI research","url":"https://pubmed.ncbi.nlm.nih.gov/32189079","citation_count":21,"is_preprint":false},{"pmid":"39423458","id":"PMC_39423458","title":"Enhancing Gpx1 palmitoylation to inhibit angiogenesis by targeting PPT1.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/39423458","citation_count":20,"is_preprint":false},{"pmid":"19793312","id":"PMC_19793312","title":"An integrated strategy for the diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven Latin American patients.","date":"2009","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19793312","citation_count":20,"is_preprint":false},{"pmid":"31578378","id":"PMC_31578378","title":"Mice deficient in the lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT1) display a complex retinal phenotype.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31578378","citation_count":19,"is_preprint":false},{"pmid":"32279353","id":"PMC_32279353","title":"Cln1-mutations suppress Rab7-RILP interaction and impair autophagy contributing to neuropathology in a mouse model of infantile neuronal ceroid lipofuscinosis.","date":"2020","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/32279353","citation_count":19,"is_preprint":false},{"pmid":"11588995","id":"PMC_11588995","title":"Pre- and postnatal enzyme analysis for infantile, late infantile and adult neuronal ceroid lipofuscinosis (CLN1 and CLN2).","date":"2001","source":"European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society","url":"https://pubmed.ncbi.nlm.nih.gov/11588995","citation_count":19,"is_preprint":false},{"pmid":"10649502","id":"PMC_10649502","title":"Identification of three novel mutations of the palmitoyl-protein thioesterase-1 (PPT1) gene in children with neuronal ceroid-lipofuscinosis.","date":"2000","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10649502","citation_count":19,"is_preprint":false},{"pmid":"26322026","id":"PMC_26322026","title":"Role of Cln1 during melanization of Cryptococcus neoformans.","date":"2015","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/26322026","citation_count":19,"is_preprint":false},{"pmid":"9256060","id":"PMC_9256060","title":"ppt-1, a Neurospora crassa PPT/PP5 subfamily serine/threonine protein phosphatase.","date":"1997","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9256060","citation_count":19,"is_preprint":false},{"pmid":"7896087","id":"PMC_7896087","title":"Three independent forms of regulation affect expression of HO, CLN1 and CLN2 during the cell cycle of Saccharomyces cerevisiae.","date":"1994","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7896087","citation_count":19,"is_preprint":false},{"pmid":"31025705","id":"PMC_31025705","title":"Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome.","date":"2019","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/31025705","citation_count":18,"is_preprint":false},{"pmid":"29762685","id":"PMC_29762685","title":"Urine Multi-drug Screening with GC-MS or LC-MS-MS Using SALLE-hybrid PPT/SPE.","date":"2018","source":"Journal of analytical toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29762685","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51898,"output_tokens":6635,"usd":0.127609,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15581,"output_tokens":5848,"usd":0.112052,"stage2_stop_reason":"end_turn"},"total_usd":0.239661,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"PPT1 (palmitoyl-protein thioesterase) encodes a 306-amino acid glycoprotein with a 25-amino-acid signal peptide, three N-linked glycosylation sites, and consensus motifs characteristic of thioesterases; it removes palmitate groups from cysteine residues in lipid-modified proteins. Northern analysis revealed ubiquitous expression of a single 2.5-kb mRNA.\",\n      \"method\": \"cDNA and genomic cloning, sequence analysis, Northern blot\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct biochemical characterization of the gene and protein structure, foundational cloning paper replicated by multiple subsequent studies\",\n      \"pmids\": [\"8786130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PPT1 disruption in knockout mice causes infantile neuronal ceroid lipofuscinosis (INCL)-like neurodegeneration with autofluorescent storage material, neuronal apoptosis, spasticity, seizures, and death by 10 months, demonstrating that PPT1 is the enzyme deficient in INCL. PPT1 hydrolyzes fatty acids from modified cysteine residues in proteins undergoing lysosomal degradation, in addition to hydrolyzing long-chain fatty acyl CoAs.\",\n      \"method\": \"Gene knockout mouse model, histopathology, enzymatic assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined neurological phenotype, enzymatic assays, replicated by multiple independent labs\",\n      \"pmids\": [\"11717424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In mouse primary neurons and brain tissue, PPT1 localizes to synaptosomes and synaptic vesicles but not to lysosomes, contrasting with its classical lysosomal routing in non-neuronal cells. PPT1 is recognized by the mannose-6-phosphate receptor (M6PR) and routed to lysosomes in COS-1 cells, with a substantial fraction secreted. In polarized epithelial cells, PPT1 localizes exclusively to the basolateral site.\",\n      \"method\": \"Confocal microscopy, cryoimmunoelectron microscopy, cell fractionation, mannose-6-phosphate receptor binding assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal localization methods (confocal, cryo-IEM, fractionation), distinct findings in neuronal vs. non-neuronal cells\",\n      \"pmids\": [\"11136716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Structural comparison of PPT1 and PPT2 crystal structures revealed that conformational differences in helix α4 create a solvent-exposed lipid-binding groove in PPT1 that is absent in PPT2, explaining why PPT1 can hydrolyze palmitoylcysteine and palmitoylated proteins while PPT2 preferentially hydrolyzes unbranched substrates like palmitoyl-CoA. Differences in the space between two parallel loops (β3-αA and β8-αF) above the lipid-binding groove account for the divergent substrate specificities.\",\n      \"method\": \"X-ray crystallography (PPT2 at 2.7 Å resolution), structural comparison with PPT1, in vitro substrate specificity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional validation of substrate specificity differences, mechanistic explanation at atomic level\",\n      \"pmids\": [\"12855696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PPT1 deficiency (Ppt1Δex4 knockout mice) causes endoplasmic reticulum stress, activation of the unfolded protein response (UPR) marked by elevated phospho-eIF2α and GRP78, and activation of caspase-12 followed by caspase-3, leading to neuronal apoptosis. The palmitoylated neuronal protein GAP-43 accumulates abnormally in the ER of PPT1-deficient cells.\",\n      \"method\": \"PPT1 knockout mouse brain analysis, forced expression of GFP-GAP-43 in PPT1-deficient cells, Western blot for UPR markers (eIF2α phosphorylation, GRP78, caspase-12 cleavage)\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple biochemical assays in both mouse model and cultured cells, replicated in related studies (PMID 16644870)\",\n      \"pmids\": [\"16368712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In human INCL brain (PPT1-deficient), ER stress-induced UPR activates caspase-4 (the human counterpart of murine caspase-12) and caspase-3, leading to apoptosis. GAP-43, a palmitoylated protein, accumulates abnormally in the ER of INCL cells. Inhibition of caspase-4 activity protects INCL cells from apoptosis.\",\n      \"method\": \"Western blot, immunofluorescence in cultured INCL cells, GFP-GAP-43 transfection and localization, caspase-4 inhibitor treatment\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Western, IF, functional rescue by inhibitor), replicated findings from murine model studies\",\n      \"pmids\": [\"16644870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PPT1 deficiency elevates reactive oxygen species (ROS) and superoxide dismutase-2 (SOD-2) levels in INCL brain and neurospheres, leading to calcium homeostasis disruption and caspase-9 activation via mitochondrial membrane destabilization, which then activates caspase-3 and PARP cleavage (apoptosis).\",\n      \"method\": \"Analysis of PPT1-KO mouse brain tissues and cultured neurospheres from PPT1-KO fetuses; measurement of ROS, SOD-2, cleaved caspase-9, caspase-3, PARP\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO model with defined biochemical readouts, single lab, pathway placement via correlation rather than direct rescue\",\n      \"pmids\": [\"16571600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PPT1's N-glycosylation at N197 and N232 (but not N212) is essential for its enzymatic activity and intracellular transport. PPT1 forms oligomeric complexes as demonstrated by size-exclusion chromatography and co-immunoprecipitation. PPT1 processing and trafficking differs between neuronal and non-neuronal cells. Disease-causing mutations increase both the degree of glycosylation of PPT1 and its ability to form complexes.\",\n      \"method\": \"Site-directed mutagenesis of glycosylation sites, size-exclusion chromatography, co-immunoprecipitation, antibody internalization assays, deglycosylation experiments\",\n      \"journal\": \"BMC cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of functional sites combined with multiple biochemical assays (SEC, Co-IP, glycosylation mutants), single lab\",\n      \"pmids\": [\"17565660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PPT1 deficiency leads to increased production of lysophosphatidylcholine (LPC), catalyzed by activation of cytosolic phospholipase A2 (cPLA2) in the PPT1-KO mouse brain. Age-dependent increases in LPC levels positively correlate with elevated expression of phagocyte-associated genes, identifying LPC as a 'lipid signal' for phagocyte recruitment contributing to INCL neuropathology.\",\n      \"method\": \"Lipid analysis of PPT1-KO mouse brain, cPLA2 activity assay, gene expression analysis, correlation of LPC levels with phagocyte markers\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical measurement of LPC and cPLA2 activity in KO model with gene expression correlation, single lab\",\n      \"pmids\": [\"17341491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PPT1 interacts with the F1-complex of mitochondrial ATP synthase (identified by co-purification and in vitro-binding assays). In Ppt1-deficient neurons, the levels of F1-subunits α and β on the plasma membrane are specifically increased. Ppt1-deficiency is also associated with changes in apolipoprotein A-I uptake and altered serum lipid composition.\",\n      \"method\": \"Co-purification, in vitro binding assays, cell surface biotinylation, TIRF-microscopy, apolipoprotein A-I uptake assays in Ppt1Δex4 mice\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-purification plus in vitro binding assay, functional consequences in KO model, single lab\",\n      \"pmids\": [\"18245779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PPT1 deficiency causes a defect in fluid-phase and receptor-mediated endocytosis (while marker uptake and recycling endocytosis remain intact), leading to hypersecretion and abnormal processing of prosaposin, resulting in accumulation of saposins A and D in PPT1-deficient fibroblasts and neurons.\",\n      \"method\": \"Endocytosis assays, metabolic labeling and immunoprecipitation of prosaposin, saposin localization by immunofluorescence in PPT1-deficient fibroblasts and mouse primary neurons\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays (endocytosis, metabolic labeling, IP), single lab, mechanistic pathway connection\",\n      \"pmids\": [\"16542649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CSPα (encoded by DNAJC5/CLN4) is a substrate of PPT1; PPT1 depalmitoylates CSPα. In DNAJC5/CLN4 patient brains, PPT1 protein is massively increased but its specific enzymatic activity is dramatically reduced and it is mis-localized. Global changes in protein palmitoylation (primarily lysosomal and synaptic proteins) occur as a consequence of PPT1 accumulation without sufficient activity.\",\n      \"method\": \"Co-immunoprecipitation, quantitative palmitoylome proteomics from patient brains, enzymatic activity assays\",\n      \"journal\": \"Acta neuropathologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzymatic substrate identification with co-IP, quantitative proteomics of palmitoylome in patient tissue, multiple orthogonal methods\",\n      \"pmids\": [\"26659577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PPT1 itself undergoes palmitoylation in vivo at cysteine-6, catalyzed by DHHC3 and DHHC7. Palmitoylation of PPT1 inhibits its depalmitoylation enzymatic activity (acts as a non-competitive inhibitor affecting Vmax) without affecting intracellular localization. The unpalmitoylated C6S mutant shows enhanced depalmitoylation activity, establishing a positive feedback loop where palmitoylation of PPT1 reduces its activity and increases substrate palmitoylation.\",\n      \"method\": \"Site-directed mutagenesis (C6S), in vitro and in vivo palmitoylation assays, DHHC enzyme co-expression, enzymatic kinetics (Vmax measurement), subcellular localization\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with enzymatic kinetics and in vivo palmitoylation assays, establishes both writer (DHHC3/7) and functional consequence\",\n      \"pmids\": [\"26731412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PPT1 is the molecular target of chloroquine (CQ) derivatives including hydroxychloroquine (HCQ), Lys05, and dimeric CQ (DC661). Using photoaffinity pulldown, CQ derivatives were shown to bind and inhibit PPT1 enzymatic activity. CRISPR/Cas9 knockout of PPT1 in cancer cells abrogates autophagy modulation and cytotoxicity of CQ derivatives and significantly impairs tumor growth.\",\n      \"method\": \"In situ photoaffinity pulldown, enzymatic activity assays, CRISPR/Cas9 PPT1 knockout in cancer cells, tumor growth assays\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding by photoaffinity pulldown, enzyme inhibition assay, genetic validation by CRISPR KO, multiple orthogonal methods\",\n      \"pmids\": [\"30442709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PPT1 is highly expressed in conventional type 1 dendritic cells (cDC1s) and promotes antigen degradation and endosomal acidification via V-ATPase recruitment, protecting DCs from viral infection. PPT1-deficient cDC1s show impaired response to VSV infection but enhanced priming of naive CD8+ T cells into KLRG1+ effectors and memory T cells. After DC activation, PPT1 is rapidly downregulated to facilitate cross-presentation.\",\n      \"method\": \"PPT1-deficient mouse models, VSV infection assays, T cell priming assays (in vivo), V-ATPase recruitment measurement, Listeria monocytogenes clearance assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function in specific cell type with defined mechanistic pathway (V-ATPase recruitment), multiple in vivo functional readouts\",\n      \"pmids\": [\"31262842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PPT1 deficiency in Cln1-/- mice disrupts Rab7 S-palmitoylation-dependent trafficking to late endosomal/lysosomal membranes, preventing Rab7-RILP interaction and autophagosome-lysosome fusion, thereby impairing autophagic degradation. Treatment with NtBuHA (a PPT1-mimetic) ameliorated this defect.\",\n      \"method\": \"Autophagy flux assays in Cln1-/- mice and INCL patient fibroblasts, Rab7 palmitoylation assays, Rab7-RILP co-immunoprecipitation, NtBuHA rescue experiments\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for Rab7-RILP interaction, palmitoylation assays, functional rescue in KO model, single lab\",\n      \"pmids\": [\"32279353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PPT1 depalmitoylates GFAP at cysteine-291, which is the unique palmitoylation site of GFAP. In PPT1-knockin mice, hyperpalmitoylated GFAP promotes astrocyte proliferation and astrogliosis. Blocking GFAP palmitoylation by mutating C291 to alanine attenuates astrogliosis and neurodegenerative pathology in PPT1-knockin mice.\",\n      \"method\": \"In vitro and in vivo palmitoylation assays, site-directed mutagenesis (C291A), astrocyte proliferation assays, histopathology of PPT1-KI mice\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — substrate identification with mutagenesis of palmitoylation site, functional rescue by mutation in disease model, multiple orthogonal methods\",\n      \"pmids\": [\"33753498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PPT1 inhibition by GNS561 results in lysosomal unbound Zn2+ accumulation, impairment of cathepsin activity, blockage of autophagic flux, altered localization of mTOR, lysosomal membrane permeabilization, and caspase activation in hepatocellular carcinoma cells.\",\n      \"method\": \"PPT1 enzymatic activity assays, lysosomal Zn2+ measurement, cathepsin activity assays, autophagy flux assays, mTOR localization by immunofluorescence, in vivo HCC models\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PPT1 enzyme inhibition with multiple downstream functional readouts, in vivo validation, single lab\",\n      \"pmids\": [\"34740311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In Cln1-/- mice (INCL model), PPT1-deficiency reduces ZDHHC5 and ZDHHC23 levels, which suppresses APT1 S-palmitoylation, causing increased membrane-localized H-Ras and activation of its proliferative signaling pathway in microglia, contributing to neuroinflammation.\",\n      \"method\": \"Western blot for ZDHHC5/ZDHHC23, APT1 palmitoylation assays, H-Ras membrane localization in Cln1-/- mouse brain, NtBuHA rescue treatment\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway identified in KO model with rescue, single lab, multiple biochemical readouts\",\n      \"pmids\": [\"33739454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PPT1 mediates depalmitoylation of Gpx1 at cysteine-76 and cysteine-113, thereby negatively regulating Gpx1 protein stability. PPT1-regulated Gpx1 depalmitoylation promotes neovascular angiogenesis; in PPT1-deficient mice, angiogenesis is attenuated in the OIR model, and PPT1 inhibition with DC661 suppresses retinal angiogenesis.\",\n      \"method\": \"Palmitoylation assays (Gpx1 palmitoylation site mapping by mutagenesis), PPT1-deficient mouse OIR model, angiogenesis assays, DC661 pharmacological inhibition\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate identification (Gpx1) with mutagenesis, in vivo disease model, pharmacological and genetic validation, single lab\",\n      \"pmids\": [\"39423458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Lipid-cysteine thioesters (substrates for PPT1) accumulate in the lysosomal fraction of PPT1-deficient cells, and their appearance is blocked by inhibitors of lysosomal proteolysis (leupeptin, chloroquine). These substrates also accumulate in normal cells after leupeptin or chloroquine treatment, demonstrating through biochemical fractionation that PPT1 acts in the lysosome to remove fatty acids from proteins undergoing lysosomal degradation.\",\n      \"method\": \"Biochemical cell fractionation, [35S]cysteine metabolic labeling, lysosomal inhibitor treatment (leupeptin, chloroquine, cysteamine), organic phase extraction and analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct biochemical demonstration of lysosomal substrate accumulation using multiple inhibitors and fractionation, mechanistically establishes site of PPT1 action\",\n      \"pmids\": [\"12069847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Over-expression of DmPpt1 (Drosophila Ppt1 ortholog) in the developing visual system leads to cell loss through apoptotic cell death. Over-expression of the catalytic site mutant DmPpt1-S123A does not cause the eye phenotype, demonstrating that cell loss depends on the catalytic activity of PPT1.\",\n      \"method\": \"Drosophila transgenic over-expression system, active-site serine-to-alanine mutagenesis (S123A), eye morphology phenotype analysis, genetic deficiency suppression\",\n      \"journal\": \"BMC neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — catalytic site mutagenesis in Drosophila model with defined phenotypic readout, demonstrates catalytic activity required for function\",\n      \"pmids\": [\"14629778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CLN3 mutations suppress the exit of cation-independent mannose-6-phosphate receptor (CI-M6PR) from the trans-Golgi network, reducing lysosomal PPT1 protein levels and PPT1 enzymatic activity in Cln3-mutant mice and JNCL patient cells. This establishes a pathway linking CLN3 function to lysosomal PPT1 delivery via CI-M6PR trafficking.\",\n      \"method\": \"Lysosomal fractionation and PPT1 enzymatic activity measurement in Cln3 mutant mice and JNCL patient fibroblasts, V0a1 v-ATPase subunit localization\",\n      \"journal\": \"Journal of inherited metabolic disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzymatic activity and protein level measurements in KO model and patient cells, pathway epistasis via CI-M6PR, single lab\",\n      \"pmids\": [\"31025705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PPT1 deficiency in Cln1-/- mice impairs the proteolytic processing of cathepsin D (CLN10/CD) precursor to its enzymatically active form in the lysosome, despite Cln10 overexpression, thereby impairing lysosomal degradative function. Treatment with NtBuHA ameliorated the cathepsin D processing defect.\",\n      \"method\": \"Western blot for cathepsin D maturation in Cln1-/- mouse brain and cultured brain cells, enzymatic activity assays, confocal microscopy, NtBuHA rescue treatment\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical demonstration of CD maturation defect with functional rescue, single lab, multiple readouts\",\n      \"pmids\": [\"26160911\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PPT1 (palmitoyl-protein thioesterase 1) is a lysosomal serine hydrolase that removes palmitate from S-acylated cysteine residues on proteins undergoing lysosomal degradation; it localizes to lysosomes in non-neuronal cells but also to synaptosomes and synaptic vesicles in neurons, requires N-glycosylation at N197/N232 for activity and transport, forms oligomeric complexes, is itself palmitoylated by DHHC3/7 (which inhibits its activity via a feedback loop), depalmitoylates substrates including GAP-43, GFAP (at C291), CSPα, Rab7, and Gpx1 to regulate their stability/trafficking, promotes endosomal acidification and V-ATPase recruitment in dendritic cells, and its deficiency triggers ER stress/UPR, impairs autophagosome-lysosome fusion via Rab7-RILP disruption, dysregulates cathepsin D maturation, and activates caspase cascades leading to neurodegeneration in infantile neuronal ceroid lipofuscinosis (INCL/CLN1 disease); pharmacologically, it is the direct molecular target of chloroquine derivatives used as autophagy inhibitors in cancer.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PPT1 is a ubiquitously expressed glycoprotein thioesterase that removes palmitate from S-acylated cysteine residues on proteins undergoing lysosomal degradation, and its loss causes infantile neuronal ceroid lipofuscinosis (INCL/CLN1 disease) [#0, #1, #20]. Biochemical fractionation localizes its catalytic action to the lysosome, where it depalmitoylates substrate proteins en route to degradation, while in neurons the enzyme is additionally found at synaptosomes and synaptic vesicles and is routed via the mannose-6-phosphate receptor [#2, #20]. Crystallographic comparison with PPT2 attributes its ability to act on palmitoylated proteins to a solvent-exposed lipid-binding groove [#3], and N-glycosylation at N197/N232 plus oligomerization are required for activity and trafficking [#7]. Catalytic activity is functionally essential, as catalytically dead enzyme fails to reproduce gain-of-function phenotypes [#21], and the enzyme is itself palmitoylated at cysteine-6 by DHHC3/DHHC7, which non-competitively inhibits its activity in a feedback loop [#12]. Identified substrates whose stability and trafficking it controls include CSP\\u03b1, Rab7, GFAP (at C291), and Gpx1 (at C76/C113) [#11, #15, #16, #19]. PPT1 deficiency triggers ER stress and the unfolded protein response with downstream caspase activation and neuronal apoptosis, disrupts Rab7-RILP-dependent autophagosome-lysosome fusion, and impairs cathepsin D maturation, collectively driving neurodegeneration [#4, #5, #15, #23]. Beyond its disease role, PPT1 promotes endosomal acidification via V-ATPase recruitment in dendritic cells [#14] and is the direct molecular target of chloroquine-derivative autophagy inhibitors used against cancer [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established the molecular identity of PPT1 as a glycosylated thioesterase that removes palmitate from lipid-modified cysteine residues, defining the enzyme to be characterized.\",\n      \"evidence\": \"cDNA/genomic cloning, sequence analysis, and Northern blot showing ubiquitous 2.5-kb transcript\",\n      \"pmids\": [\"8786130\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates not yet identified\", \"Subcellular site of action not yet established\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Linked PPT1 loss to a defined neurodegenerative disease, showing the enzyme is deficient in INCL and acts on cysteine-modified proteins undergoing lysosomal degradation.\",\n      \"evidence\": \"PPT1 knockout mouse with INCL-like neuropathology plus enzymatic assays\",\n      \"pmids\": [\"11717424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific disease-driving substrates undefined\", \"Molecular cascade from enzyme loss to apoptosis unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved the cell-type-specific routing of PPT1, distinguishing classical M6PR-dependent lysosomal targeting in non-neuronal cells from synaptic localization in neurons.\",\n      \"evidence\": \"Confocal/cryo-IEM, fractionation, and M6PR binding across neuronal, COS-1, and polarized epithelial cells\",\n      \"pmids\": [\"11136716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism directing neuronal synaptic localization unclear\", \"Functional role at synaptic vesicles undefined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated that PPT1 acts within the lysosome to remove fatty acids from proteins during degradation, fixing the site of catalytic action.\",\n      \"evidence\": \"Biochemical fractionation with [35S]cysteine labeling and lysosomal protease/acidification inhibitors\",\n      \"pmids\": [\"12069847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of accumulating thioester substrates not defined\", \"Does not address extralysosomal neuronal pools\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Provided the structural basis for PPT1's substrate specificity, explaining why it acts on palmitoylated proteins whereas PPT2 prefers unbranched acyl-CoA.\",\n      \"evidence\": \"X-ray crystallography of PPT2, structural comparison with PPT1, and in vitro substrate specificity assays\",\n      \"pmids\": [\"12855696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal with a protein substrate\", \"Catalytic mechanism detail on intact proteins untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showed that PPT1 function in vivo depends on its catalytic activity, ruling out a purely structural role.\",\n      \"evidence\": \"Drosophila over-expression of wild-type vs. catalytic-mutant (S123A) DmPpt1 with eye phenotype readout\",\n      \"pmids\": [\"14629778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Over-expression phenotype not directly equivalent to loss-of-function disease\", \"Mammalian substrate relevance not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined a death pathway downstream of PPT1 loss: ER accumulation of palmitoylated GAP-43 triggers UPR and caspase-mediated neuronal apoptosis.\",\n      \"evidence\": \"PPT1-KO mouse brain and GFP-GAP-43 expression with UPR/caspase Western blots\",\n      \"pmids\": [\"16368712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GAP-43 causal contribution to disease not proven by rescue\", \"Other accumulating substrates not enumerated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Extended the apoptotic mechanism to human INCL and to additional death branches (oxidative/mitochondrial), confirming caspase-driven neurodegeneration.\",\n      \"evidence\": \"Human INCL cells with caspase-4 inhibition rescue; KO brain/neurosphere ROS, SOD-2, caspase-9/3, PARP measurements\",\n      \"pmids\": [\"16644870\", \"16571600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of ER-stress vs. mitochondrial pathways unquantified\", \"Caspase-9 pathway placement by correlation, not rescue\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected PPT1 loss to broader lysosomal/endocytic dysfunction by showing impaired endocytosis and aberrant prosaposin processing.\",\n      \"evidence\": \"Endocytosis assays, metabolic labeling/IP of prosaposin, and saposin localization in PPT1-deficient fibroblasts and neurons\",\n      \"pmids\": [\"16542649\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between PPT1 activity and endocytic machinery unidentified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined post-translational and assembly requirements for PPT1, showing N197/N232 glycosylation and oligomerization are needed for activity and trafficking.\",\n      \"evidence\": \"Site-directed mutagenesis of glycosylation sites, SEC, co-IP, and deglycosylation experiments\",\n      \"pmids\": [\"17565660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of oligomerization not resolved\", \"Why disease mutants hyperglycosylate unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified a lipid-signaling consequence of PPT1 loss linking enzyme deficiency to phagocyte-driven neuroinflammation via LPC accumulation.\",\n      \"evidence\": \"Brain lipid analysis, cPLA2 activity, and gene expression correlation in PPT1-KO mice\",\n      \"pmids\": [\"17341491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"cPLA2 activation mechanism downstream of PPT1 loss undefined\", \"Causal role of LPC in pathology shown only by correlation\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Reported a non-canonical PPT1 interaction with mitochondrial ATP synthase F1-complex and altered lipoprotein handling, broadening its functional context.\",\n      \"evidence\": \"Co-purification, in vitro binding, cell-surface biotinylation/TIRF, and ApoA-I uptake assays in Ppt1-deficient mice\",\n      \"pmids\": [\"18245779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional significance of the F1-complex interaction unresolved\", \"Single co-purification without reciprocal validation\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Began identifying specific physiological substrates and processing roles: CSP\\u03b1 as a PPT1 substrate and cathepsin D maturation dependence on PPT1.\",\n      \"evidence\": \"Co-IP and palmitoylome proteomics from DNAJC5/CLN4 patient brains; cathepsin D maturation Westerns with NtBuHA rescue in Cln1-/- mice\",\n      \"pmids\": [\"26659577\", \"26160911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which PPT1 controls cathepsin D processing indirect\", \"Causality between palmitoylome shifts and disease not fully resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed autoregulation: PPT1 is palmitoylated at Cys6 by DHHC3/7, which non-competitively inhibits its activity, establishing a feedback loop controlling global palmitoylation.\",\n      \"evidence\": \"C6S mutagenesis, in vitro/in vivo palmitoylation assays, DHHC co-expression, and enzyme kinetics\",\n      \"pmids\": [\"26731412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological conditions regulating PPT1 palmitoylation unknown\", \"Impact on disease progression untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified PPT1 as the direct molecular target of chloroquine-derivative autophagy inhibitors, repurposing it as an anticancer drug target.\",\n      \"evidence\": \"In situ photoaffinity pulldown, enzyme inhibition assays, and CRISPR PPT1 knockout with tumor growth assays\",\n      \"pmids\": [\"30442709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding-site structural detail not resolved\", \"Substrate(s) mediating the autophagy-modulating effect undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a cell-type-specific physiological role in dendritic cells, where PPT1 drives V-ATPase-dependent endosomal acidification and antigen degradation, balancing antiviral defense against T cell priming.\",\n      \"evidence\": \"PPT1-deficient mice, VSV infection, in vivo T cell priming, V-ATPase recruitment, and Listeria clearance assays\",\n      \"pmids\": [\"31262842\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct V-ATPase substrate/palmitoylation link not defined\", \"Relationship to neuronal PPT1 function unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed PPT1 in the broader NCL network by showing CLN3 controls lysosomal PPT1 delivery via CI-M6PR trafficking.\",\n      \"evidence\": \"Lysosomal fractionation and PPT1 activity in Cln3-mutant mice and JNCL patient cells\",\n      \"pmids\": [\"31025705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CLN3-CI-M6PR mechanism not fully resolved\", \"Single-lab epistasis\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Mechanistically linked PPT1 loss to autophagy failure through defective Rab7 palmitoylation, blocking Rab7-RILP interaction and autophagosome-lysosome fusion.\",\n      \"evidence\": \"Autophagy flux, Rab7 palmitoylation, Rab7-RILP co-IP, and NtBuHA rescue in Cln1-/- mice and patient fibroblasts\",\n      \"pmids\": [\"32279353\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct demonstration that Rab7 is a PPT1 catalytic substrate incomplete\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded the substrate repertoire and disease mechanism through GFAP (C291) depalmitoylation controlling astrogliosis, and a microglial ZDHHC/APT1/H-Ras axis driving neuroinflammation.\",\n      \"evidence\": \"Palmitoylation assays and C291A mutagenesis in PPT1-knockin mice; ZDHHC5/23, APT1 palmitoylation, and H-Ras localization with NtBuHA rescue in Cln1-/- mice\",\n      \"pmids\": [\"33753498\", \"33739454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GFAP/H-Ras contributions to overall disease severity not quantified\", \"Microglial axis is single-lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Characterized the downstream lysosomal consequences of pharmacological PPT1 inhibition in cancer: Zn2+ accumulation, cathepsin impairment, autophagy blockade, and lysosomal membrane permeabilization.\",\n      \"evidence\": \"GNS561 PPT1 inhibition with lysosomal Zn2+, cathepsin, autophagy flux, mTOR localization, and in vivo HCC assays\",\n      \"pmids\": [\"34740311\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PPT1 substrate mediating these effects undefined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Added Gpx1 (C76/C113) as a PPT1 substrate whose depalmitoylation destabilizes the protein and drives neovascular angiogenesis, extending PPT1 function beyond neurodegeneration.\",\n      \"evidence\": \"Gpx1 palmitoylation-site mapping, PPT1-deficient OIR mouse model, and DC661 inhibition in angiogenesis assays\",\n      \"pmids\": [\"39423458\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue specificity of Gpx1 regulation unclear\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PPT1 substrate selection is governed in different compartments (lysosome vs. synapse vs. endosome) and which specific depalmitoylation events are causally rate-limiting for INCL and for cancer drug response remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking individual substrate effects to disease severity\", \"Structural basis of inhibitor and substrate binding incomplete\", \"Mechanism of neuronal non-lysosomal targeting unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 11, 16, 19, 20]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 3, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [2, 20, 22]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [10, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13, 15, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 4, 5, 22]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [11, 16, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"DHHC3\", \"DHHC7\", \"Rab7\", \"RILP\", \"CSPalpha\", \"GFAP\", \"Gpx1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}